Moving toward Personalized Medicine in the Methadone Maintenance Treatment Program: A Pilot Study on the Evaluation of Treatment Responses in Taiwan

Table 6

Variables significantly associated with nonresponders in the Taiwan methadone maintenance treatment program (MMTP)^a.

Variable	AOR^c	95 % CI^d	𝑃 value
Sex
Female (versus male)	0.44	0.86–6.24	0.09
CYP2B6 A785G (*4)
A/G, G/G (versus A/A)	1.74	0.89–3.46	0.10
ABCB1 G2677T/A
G/T, T/T (versus G/G)	0.48	0.23–1.01	0.05
Psychiatric disorders^b	2.71	1.10–6.53	0.02*
Alcohol use history	2.25	1.12–4.59	0.02*
HCV	6.42	1.14–121.3	0.03*

aAge, marital status, tobacco use, betel nut use, current amphetamine use, treatment duration, HBV, pain disorders, depression, anxiety, methadone maintenance dose, CYP2B6 G516T, CYP2C19 G681A/C, G636A, C3402T, ABCB1 C1236T, and C3435T were not significantly associated. In the multiple logistic regression model, variables were selected using mixed stepwise regression; 𝑃 value for model: 0.0002.
^bPsychiatric disorders included schizophrenic disorders, hallucinosis, paranoia, panic disorders, and neurotic disorders.
^cAOR, adjusted odds ratio.
^d95% CI, 95% confidence interval.